

PROVIDER BULLETIN

PROVIDER INFORMATION



April 1, 2022

Medical Policy Updates: Coupe Health and Self-Funded Benefit Plans Managed by Blue Cross and Blue Shield of Alabama

Participating providers are invited to submit for consideration scientific, evidence-based information, professional consensus opinions, and other information supported by medical literature relevant to our draft policies for Coupe Health and Self-Funded benefit plans managed by Blue Cross and Blue Shield of Alabama.

The draft policies are available for physician comment for 45 days from the posting date found on the document. Make sure your voice is heard by providing feedback directly to us.

How to Submit Comments on Draft Medical Policies

Complete our medical policy feedback form online at <https://mn-policies.exploremyplan.com/portal/web/mn-policies/feedback> or send comments and supporting documentation to us by mail or fax:

Birmingham Service Center
Attn: Health Management - Medical Policy
P.O. Box 10527
Birmingham, AL 35202
Fax: 205-220-0878

Draft Medical Policies

Draft medical policies can be found at [Policies & Guidelines \(exploremyplan.com\)](https://mn-policies.exploremyplan.com/portal/web/mn-policies/guidelines)

Policy #	Policy Title
MP-306	Intraoperative Neurophysiologic Monitoring
MP-746	Maternal Serum Biomarkers for Prediction of Adverse Obstetric Outcomes
MP-744	Cryoablation, Radiofrequency Ablation, and Laser Ablation for the Treatment of Chronic Rhinitis
MP-312	Suprachoroidal Delivery of Pharmacological Agents
MP-208	Laparoscopic, Percutaneous, and Transcervical Techniques for the Myolysis of Uterine Fibroids
MP-513	Genetic Testing for Hereditary Breast and/or Ovarian Cancer

Draft Provider-Administered Drug Policies

Draft provider-administered drug policies can be found at [Policies & Guidelines \(exploremyplan.com\)](https://mn-policies.exploremyplan.com/portal/web/mn-policies/guidelines) and [Policies & Guidelines \(exploremyplan.com\)](https://mn-policies.exploremyplan.com/portal/web/mn-policies/guidelines)

Policy #	Policy Title
PH-9260	Nucala [®] (mepolizumab)
PH-90006	Aldurazyme [®] (laronidase)
PH-90299	Brineura (cerliponase alfa)

Bulletin P19-22

Distribution: bluecrossmn.com/providers/forms-and-publications

Blue Cross[®] and Blue Shield[®] of Minnesota and Blue Plus[®] are nonprofit independent licensees of the Blue Cross and Blue Shield Association.

L08R04 (12/13)

PH-90034	Elaprase [®] (idursulfase)
PH-90061	Hyaluronic Acid Derivatives: Durolane [®] , Euflexxa [™] , Gel-One [®] , GelSyn-3 [™] , GenVisc 850 [®] , Hyalgan [™] , Hymovis [®] , Monovisc [®] , Orthovisc [™] , Supartz/Supartz FX [™] , Synvisc [™] , Synvisc-One [™] , Triluron [™] , TriVisc [™] , VISCO-3 [™] , & sodium hyaluronate 1%
PH-90104	Infliximab: Remicade [®] ; Inflectra [™] ; Renflexis [™] ; Avsola [™]
PH-90277	Kanuma [™] (sebelipase alfa)
PH-90079	Lumizyme [®] (alglucosidase alfa)
PH-90346	Mepsevii [™] (vestronidase alfa-vjbk)
PH-90084	Naglazyme [®] (galsulfase)
PH-90615	Nexviazyme [™] (avalglucosidase alfa-ngpt)
PH-90089	Nplate [®] (romiplostim)
PH-90190	Vimizim [®] (elosulfase alfa)
PH-9405	Onasemnogene Apeparvovec (Zolgensma)
PH-90652	Leqvio [®] (inclisiran)
PH-09650	Tezspire [™] (tezepelumab-ekko)
PH-90649	Vyvgart [™] (efgartigimod alfa-fcab)